To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Epigenetic MGMT Test Enters Phase III Brain Cancer Study
MDxHealth's epigenetic MGMT test (PredictMDx(TM) for Glioblastoma) will be used to select patients to enroll in a randomized, multicenter phase III clinical study examining the addition of lomustine (also known as CCNU) to the current therapy of temozolomide/radiotherapy in MGMT methylated, newly diagnosed glioblastoma multiforme (GBM) patients, a severe form of brain cancer. The study, called CeTeG, will start recruiting patients this month and will last for approximately 2 years. Financial terms of the deal were not disclosed.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
